Home > Insider Trading > Filing (0000899243-21-012695)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1599901	Avidity Biosciences Inc.	RNA	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1181556	A Arthur Levin	C/O Avidity Biosciences, Inc. 10975 N. Torrey Pines Road, Suite 150 La Jolla CA 92037	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-03-05	37,022	$0.00	273,872	No	5	G	Indirect	By family trust
Common Stock	Acquisiton	2021-03-05	37,022	$0.00	37,022	No	5	G	Indirect	By charitable remainder trust
Common Stock	Acquisiton	2021-03-16	2,625	$1.24	2,625	No	4	M	Direct
Common Stock	Acquisiton	2021-03-16	1,975	$0.53	4,600	No	4	M	Direct
Common Stock	Disposition	2021-03-16	4,600	$27.87	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	5	G	Indirect	By family trust
No	5	G	Indirect	By charitable remainder trust
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-03-16	2,625	$0.00	2,625	$1.24
Common Stock	Stock Option (Right to Buy)	Disposition	2021-03-16	1,975	$0.00	1,975	$0.53

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
208,483		2030-02-18	No	4	M	Direct
45,430		2027-08-28	No	4	M	Direct

Footnotes

The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.8571 to $27.8739. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter.
This option is exercisable as to vested and unvested shares. The option was granted on August 29, 2017 and 1/48th of the shares subject to the option vest monthly.